Mita et al. isolated SEPP1-neutralizing antibodies that improved glucose tolerance, IR, and insulin secretion in a T2DM mouse model, suggesting that elevated SEPP1 levels are an effective target for T2DM treatment [132]. Here, INS is linked to type 2 diabetes mellitus.